Solutions
Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
Insights
Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.
Our Solutions
News and Events
Panel: Drug Pricing and Value Based Reimbursement
Jeff Berkowitz
Real Endpoints
Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors -- about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.
October 13, 2019
-
October 15, 2019
Laguna Beach, CA
Real Endpoints: Research supports expanding insurance coverage of non-invasive prenatal testing
by University of Colorado
Research conducted by the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provides evidence to support expansion of insurance plan coverage of noninvasive prenatal testing (NIPT), to women under the age of 35. It represents a first-of-its-kind published analysis of results from a risk-sharing agreement between biotechnology company Illumina, Inc. and insurer Harvard Pilgrim Health Care, conducting the research in partnership with advisory firm Real Endpoints to evaluate the impacts of the agreement.
Congratulations Susan!
Susan Raiola – President of Real Endpoints, was chosen as one of PharmaVOICE’s Top 100 most inspiring people in the pharma industry. These inspirational leaders, representing a wide range of industry sectors and functional areas, have an extraordinary and positive impact on their colleagues, their companies, and the life-sciences ecosystem.
Recent Insights
view archive >
June 11, 2019
Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
Access to new gene therapies may be impacted by payer ability to absorb the cost of coverage. Payers are open to innovative financing models that improve financial predictability and reward clinical performance.
read full insight article >
February 13, 2019
Examining New Payment Ideas for Curative Therapies
How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Jane F. Barlow, MD, MPH, MBA, was a speaker at the FoCUS (Financing and Reimbursement of Cure in US) Project at MIT, during the session "Putting Theory into Practice" she was quoted saying the “accessibility issue lies largely with payers.” All payers are different, and “a lot has to do with how they manage risk in their population as well as the regulatory constraints."
read full insight article >National Business Director
Top 5 Pharma
Senior Director
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
Jack Bailey
President , GlaxoSmithKline U.S.